- Acton MA, US Joon Bok LEE - Acton MA, US Jason O'CONNOR - Acton MA, US
International Classification:
A61M 5/172 G16H 20/17 A61B 5/145 A61M 5/142
Abstract:
Disclosed are techniques, a system and devices that enable the setting of an upper boundary constraint that may be a multiple of a total daily dosage setting for a liquid drug being administered to a user to control a condition, such as type 1 or type 2 diabetes mellitus. An automatic drug delivery algorithm may be configured to obtain a glucose control metric. A controller executing the automatic drug delivery algorithm may ascertain, based on the glucose control metric, an upper boundary constraint for the liquid drug that limits an amount of a dose of the liquid drug that may be delivered by the automatic drug delivery system or components thereof.
Automated Insulin Delivery System Using Pramlintide
Disclosed herein are systems and methods for the delivery of insulin and pramlintide using an automated insulin delivery system. In a first embodiment, a drug delivery system is configured to deliver independent doses of insulin and pramlintide. The system monitors the user's blood glucose level and determines when a meal is been ingested and, in response, delivers the dose of pramlintide which, in turn alters the required delivery of insulin. In the second embodiment, the drug delivery system is configured to deliver a co-formulation of insulin and pramlintide as basal doses. The total amount of pramlintide delivered in a most recent pre-determine period of time, for example, 24 hours, is used to alter the aggressiveness of the algorithm which determines the basal doses of the co-formulation.
Systems And Methods For Incorporating Co-Formulations Of Insulin In An Automatic Insulin Delivery System
- Acton MA, US Jason O'CONNOR - Acton MA, US Yibin ZHENG - Hartland WI, US Ashutosh ZADE - San Diego CA, US
International Classification:
A61M 5/172 G16H 20/17
Abstract:
Disclosed herein are systems and methods for the delivery of a co-formulation of insulin and a second drug, such as GLP-1, using an automated insulin delivery system. In a first embodiment, a dose of insulin is calculated by a medication delivery algorithm and a reduction factor is applied to account for the effect of second drug on the user's daily insulin requirement. In a second embodiment of the invention, a total amount of the second drug administered to the user during the past 24 hours is used to modify the correction factor and the insulin-to-carbohydrate ratio used by the medication delivery algorithm to cause a reduction in the insulin delivered to the user to account for the effect of the administration of the second drug portion of the co-formulation.
Compensation For Missing Readings From A Glucose Monitor In An Automated Insulin Delivery System
- Acton MA, US Joon Bok LEE - Acton MA, US Ashutosh ZADE - San Diego CA, US Jason O'CONNOR - Acton MA, US
International Classification:
A61M 5/172 G06F 17/17
Abstract:
Exemplary embodiments may address the problem of missing blood glucose concentration readings from a glucose monitor that transmits blood glucose concentration readings over a wireless connection due to problems with the wireless connection. In the exemplary embodiments, an automated insulin delivery (AID) device uses an estimate in place of a missing blood glucose concentration reading in determining a predicted future blood glucose concentration reading for a user. Thus, the AID device is able to operate normally in generating insulin delivery settings despite not receiving a current blood glucose concentration reading for a current cycle. There is no need to suspend delivery of insulin to the user due to the missing blood glucose concentration reading.
Fluid Delivery Device, Transcutaneous Access Tool And Fluid Drive Mechanism For Use Therewith
A fluid delivery device comprising a fluid reservoir; a transcutaneous access tool fluidly coupled to the fluid reservoir; and a drive mechanism for driving fluid from the reservoir, the drive mechanism comprising a plunger received in the reservoir; a leadscrew extending from the plunger; a nut threadably engaged with the leadscrew; a drive wheel; and a clutch mechanism coupled to the drive wheel, wherein the clutch mechanism is configured to allow the nut to pass through when disengaged and is configured to grip the nut when engaged such that the drive wheel rotates the nut to advance the drive rod and the plunger into the reservoir.
Scheduling Of Medicament Bolus Deliveries By A Medicament Delivery Device At Future Dates And Times With A Computing Device
Exemplary embodiments may enable a user to schedule medicament bolus deliveries, such as insulin boluses, for future dates and times. The exemplary embodiments may provide the ability to delay a scheduled medicament bolus delivery by short periods of time. The user may reschedule a scheduled medicament bolus delivery by entering a new date and/or time for the medicament bolus delivery. Still further, a user may cancel a scheduled medicament bolus delivery. In addition, exemplary embodiments may enable multiple medicament bolus deliveries to be viewed and managed.
Initial Total Daily Insulin Setting For User Onboarding
Disclosed are techniques to establish initial settings for an automatic insulin delivery device. An adjusted total daily insulin (TDI) factor usable to calculate a TDI dosage may be determined. The adjusted TDI factor may be a TDI per unit of a physical characteristic of the user (e.g., weight) times a reduction factor. The adjusted TDI factor may be compared to a maximum algorithm delivery threshold. Based on the comparison result, the application or algorithm may set a TDI dosage and output a control signal. Blood glucose measurement values may be collected from a sensor over a period of time. A level of glycated hemoglobin of the blood may be determined based on the obtained blood glucose measurement values. In response to the level of glycated hemoglobin, the set TDI dosage may be modified. A subsequent control signal including the modified TDI dosage may be output to actuate delivery of insulin.
Compensation For Missing Readings From A Glucose Monitor In An Automated Insulin Delivery System
- Acton MA, US Joon Bok LEE - Acton MA, US Ashutosh ZADE - San Diego CA, US Jason O'Connor - Acton MA, US
Assignee:
INSULET CORPORATION - Acton MA
International Classification:
A61M 5/172 G06F 17/17
Abstract:
Exemplary embodiments may address the problem of missing blood glucose concentration readings from a glucose monitor that transmits blood glucose concentration readings over a wireless connection due to problems with the wireless connection. In the exemplary embodiments, an automated insulin delivery (AID) device uses an estimate in place of a missing blood glucose concentration reading in determining a predicted future blood glucose concentration reading for a user. Thus, the AID device is able to operate normally in generating insulin delivery settings despite not receiving a current blood glucose concentration reading for a current cycle. There is no need to suspend delivery of insulin to the user due to the missing blood glucose concentration reading.